Time to Revisit Using 10-Year Risk to Guide Statin Therapy.
Publication
, Journal Article
Navar, AM; Fonarow, GC; Pencina, MJ
Published in: JAMA Cardiol
August 1, 2022
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
JAMA Cardiol
DOI
EISSN
2380-6591
Publication Date
August 1, 2022
Volume
7
Issue
8
Start / End Page
785 / 786
Location
United States
Related Subject Headings
- Primary Prevention
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Humans
- Cardiovascular Diseases
- 3201 Cardiovascular medicine and haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Navar, A. M., Fonarow, G. C., & Pencina, M. J. (2022). Time to Revisit Using 10-Year Risk to Guide Statin Therapy. JAMA Cardiol, 7(8), 785–786. https://doi.org/10.1001/jamacardio.2022.1883
Navar, Ann Marie, Gregg C. Fonarow, and Michael J. Pencina. “Time to Revisit Using 10-Year Risk to Guide Statin Therapy.” JAMA Cardiol 7, no. 8 (August 1, 2022): 785–86. https://doi.org/10.1001/jamacardio.2022.1883.
Navar AM, Fonarow GC, Pencina MJ. Time to Revisit Using 10-Year Risk to Guide Statin Therapy. JAMA Cardiol. 2022 Aug 1;7(8):785–6.
Navar, Ann Marie, et al. “Time to Revisit Using 10-Year Risk to Guide Statin Therapy.” JAMA Cardiol, vol. 7, no. 8, Aug. 2022, pp. 785–86. Pubmed, doi:10.1001/jamacardio.2022.1883.
Navar AM, Fonarow GC, Pencina MJ. Time to Revisit Using 10-Year Risk to Guide Statin Therapy. JAMA Cardiol. 2022 Aug 1;7(8):785–786.
Published In
JAMA Cardiol
DOI
EISSN
2380-6591
Publication Date
August 1, 2022
Volume
7
Issue
8
Start / End Page
785 / 786
Location
United States
Related Subject Headings
- Primary Prevention
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Humans
- Cardiovascular Diseases
- 3201 Cardiovascular medicine and haematology